Successful treatment of unresectable gallbladder cancer with low-dose paclitaxel as palliative chemotherapy after failure of gemcitabine and oral S-1: A case report

Tajima,Hidehiro; Ohta,Tetsuo; Shinbashi,Hiroyuki; Hirose,Atsushi; Tsukada,Tomoya; Okamoto,Koichi; Nakanuma,Shinichi; Sakai,Seisho; Furukawa,Hiroyuki; Makino,Isamu; Nakamura,Keishi; Hayashi,Hironori; Oyama,Katsunobu; Inokuchi,Masafumi; Nakagawara,Hisatoshi; Miyashita,Tomoharu; Fujita,Hideto; Takamura,Hiroyuki; Ninomiya,Itasu; Kitagawa,Hirohisa; Fushida,Sachio; Fujimura,Takashi; Mouri,Hisatsugu; Ohtsubo,Koushiro

doi:10.3892/ol.2012.909

December 2012 Volume 4 Issue 6

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

December 2012 Volume 4 Issue 6

Full Size Image

Case Report

Successful treatment of unresectable gallbladder cancer with low-dose paclitaxel as palliative chemotherapy after failure of gemcitabine and oral S-1: A case report

Authors:
- Hidehiro Tajima
- Tetsuo Ohta
- Hiroyuki Shinbashi
- Atsushi Hirose
- Tomoya Tsukada
- Koichi Okamoto
- Shinichi Nakanuma
- Seisho Sakai
- Hiroyuki Furukawa
- Isamu Makino
- Keishi Nakamura
- Hironori Hayashi
- Katsunobu Oyama
- Masafumi Inokuchi
- Hisatoshi Nakagawara
- Tomoharu Miyashita
- Hideto Fujita
- Hiroyuki Takamura
- Itasu Ninomiya
- Hirohisa Kitagawa
- Sachio Fushida
- Takashi Fujimura
- Hisatsugu Mouri
- Koushiro Ohtsubo
View Affiliations / Copyright

Affiliations: Department of Gastroenterologic Surgery, Division of Cancer Medicine, Graduate School of Medical Science, Kanazawa University, Kanazawa, Japan, Division of Medical Oncology, Cancer Research Institute, Kanazawa University, Japan
Pages: 1281-1284
|
Published online on: September 12, 2012

https://doi.org/10.3892/ol.2012.909
Expand metrics +

Abstract

A 56-year-old female with metastatic gallbladder cancer involving the liver and stenosis of the hilar bile duct was treated with gemcitabine (1,000 mg/m2) plus S-1 (60 mg/m2). After 9 cycles of therapy, CT showed evidence of stable disease; however, the serum CEA level was increased. Therefore, the chemotherapy regimen was changed to weekly low-dose paclitaxel (60 mg/m2). After 12 cycles of therapy, paclitaxel was reduced to 30 mg/m2 as the patient developed neutropenia. The patient completed 32 cycles of therapy, and the tumor was reduced in size and marked improvement in bile duct stenosis was noted without any impairment in quality of life. The patient succumbed to the disease 25 months after treatment was initiated. Thus, in this case paclitaxel was more effective than gemcitabine plus S-1. Palliative chemotherapy with paclitaxel after failure of gemcitabine and 5-FU was well‑tolerated; therefore, it may be an effective treatment for biliary tract cancer (BTC). A phase I study of palliative chemotherapy with weekly low-dose paclitaxel following gemcitabine (plus cisplatin) and 5-FU is currently in progress in patients with unresectable or recurrent BTC.

View Figures

View References

1.	AX XiuTS HongAF HezelDA KoobyCurrent management of gallbladder carcinomaOncologist15168181201010.1634/theoncologist.2009-0302
2.	JW ValleH WasanDH PalmerABC-02 Trial Investigators: Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancerN Engl J Med36212731281201010.1056/NEJMoa090872120375404
3.	K GelmonThe toxoids: paclitaxel and docetaxelLancet34412671272199410.1016/S0140-6736(94)90754-47967989
4.	KL DonaldsonGL GoolsbyPA KienerAF WahlActivation of p34cdc2 coincident with taxol-induced apoptosisCell Growth Differ51041105019947848905
5.	PB SchiffJ FantSB HorwitzPromotion of microtubule assembly in vitro by taxolNature277665667197910.1038/277665a0423966
6.	D ZhangL SunW XianF LiuLow-dose paclitaxel ameliorates renal fibrosis in rat UUO model by inhibition of TGF-beta/Smad activityLab Invest90436447201010.1038/labinvest.2009.14920142807
7.	J ZhouDW ZhongQW WangXY MiaoXD XuPaclitaxel ameliorates fibrosis in hepatic stellate cells via inhibition of TGF-beta/Smad activityWorld J Gastroenterol1633303334201010.3748/wjg.v16.i26.333020614491
8.	H TajimaT OhtaH KitagawaPilot study of neoadjuvant chemotherapy with gemcitabine and oral S-1 for resectable pancreatic cancerExp Therap Med3787792201222969969
9.	PA EllisA NormanA HillME O’BrienM NicolsonT HickishD CunninghamEpirubicin, cisplatin and infusional 5-fluorouracil (5-FU) (ECF) in hepatobiliary tumorsEur J Cancer31A15941598199510.1016/0959-8049(95)00323-B7488407
10.	YZ PattDV Jones JrA HoqueR LozanoA MarkowitzI RaijmanP LynchC CharnsangavejPhase II trial of intravenous fluorouracil and subcutaneous interferon alfa-2b for biliary tract cancerJ Clin Oncol142311231519968708722
11.	T IokaM IkedaS OhkawaRandomized phase III study of gemcitabine plus S-1 (GS) versus S-1 versus gemcitabine (GEM) in unresectable advanced pancreatic cancer (PC) in Japan and Taiwan: GEST studyJ Clin Oncol29Supplabstr 40072011
12.	P PapakostasC KouroussisN AndroulakisFirst-line chemotherapy with docetaxel for unresectable or metastatic carcinoma of the biliary tract. A multicentre phase II studyEuro J Cancer3718331838200110.1016/S0959-8049(01)00214-311576836
13.	S OkadaY SakataS MatsunoPhase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study. Cooperative Group of Docetaxel for Pancreatic Cancer in JapanBr J Cancer80438443199910.1038/sj.bjc.669037510408850
14.	DP RyanMH KulkeCS FuchsA Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinomaCancer9497103200210.1002/cncr.1020211815964
15.	DV Jones JrR LozanoA HoqueA MarkowitzYZ PattPhase II study of paclitaxel therapy for unresectable biliary tree carcinomasJ Clin Oncol142306231019968708721
16.	S MaedaF MotoiT OnogawaPaclitaxel as second-line chemotherapy in patients with gemcitabine-refractory pancreatic cancer: a retrospective studyInt J Clin Oncol16539545201110.1007/s10147-011-0220-821455624
17.	DD Von HoffRK RamanthanMJ BoradGemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trialJ Clin Oncol2945484554201121969517
18.	I BaekCZ BaiJ HwangHY NamJS ParkDJ KimPaclitaxel coating of the luminal surface of hemodialysis grafts with effective suppression of neointimal hyperplasiaJ Vasc Surg55806814201210.1016/j.jvs.2011.09.01222226184
19.	HS ChoiCE SavardJW ChoiR KuverSP LeePaclitaxel interrupts TGF-beta1 signaling between gallbladder epithelial cells and myofibroblastsJ Surg Res141183191200710.1016/j.jss.2006.12.55817574589
20.	AG TaghianR Abi-RaadSI AssaadPaclitaxel decreases the interstitial fluid pressure and improves oxygenation in breast cancer in patients treated with neoadjuvant chemotherapy: clinical implicationsJ Clin Oncol2319511961200510.1200/JCO.2005.08.119
21.	T ShukuyaH YasuiN Bokupaclitaxel after failure of gemcitabine in pancreatic cancer patients with malignant ascites: a retrospective studyJpn J Clin Oncol4011351138201010.1093/jjco/hyq11720656694
22.	S CeredaM ReniWeekly docetaxel as salvage therapy in patients with gemcitabine-refractory metastatic pancreatic cancerJ Chemother20509512200810.1179/joc.2008.20.4.50918676234
23.	H TajimaT OhtaY ShojiExpression of epithelial-mesenchymal transition markers in locally recurrent hepatocellular carcinoma after radio frequency ablationExp Therap Med1347350201010.3892/etm_00000054
24.	JG SchramaMM de BoerJW BaarsJH SchornagelS RodenhuisPalliative chemotherapy after failure of high-dose chemotherapy in breast cancer - toxicity and efficacyAnticancer Res2327952800200312926115

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Successful treatment of unresectable gallbladder cancer with low-dose paclitaxel as palliative chemotherapy after failure of gemcitabine and oral S-1: A case report

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Figure 4

Related Articles